Anti-MHC class II Antibody-Cytokine Fusion Protein, IgG (chCLL-1)-GM-CSF (CAT#: ACFP-SH024)

This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-MHC class II IgG to GM-CSF. It was expressed in CHO and purified with affinity chromatography. This antibody-cytokine fusion protein retains GM-CSF bioactivity, evaluated by its ability to induce the formation of hematopoietic progenitor colonies from bone marrow mononuclear cells, and also retains the ability to bind the antigens on the surface of cancer cells that express MHC class II. It also demonstrated ADCC in vitro, using human mononuclear cells as effectors. This immunocytokine was designed for treating B-cell NHL and chronic lymphocytic leukemia.